Drug intelligence / Profile preview

Sante FX V+

Development stage
Unknown
Lead developer
Santen Pharmaceutical
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

## Sante FX V+\nSante FX V+ is a Japanese over-the-counter ophthalmic combination drug developed and manufactured by Santen for symptomatic relief of eye fatigue and irritation. It is a multi-ingredient small-molecule eye drop containing pyridoxine hydrochloride, taurine, potassium L-aspartate, neostigmine methylsulfate, tetrahydrozoline hydrochloride, chlorpheniramine maleate, and epsilon-aminocaproic acid. The formulation combines nutritional and metabolic support components with a parasympathomimetic agent that can aid accommodative function, a vasoconstrictor that reduces conjunctival hyperemia, an antihistamine that reduces itching and irritation, and an anti-inflammatory or antifibrinolytic component used in ophthalmic irritation. It is marketed in Japan as a cooling eye drop for eye fatigue, conjunctival redness, itchy eyes, prevention of eye diseases, ocular inflammation caused by ultraviolet rays or other light exposure, blurred vision, blepharitis, and discomfort associated with hard contact lens use.

Brand names
Sante FX V+Sante FX V Plus
02

Targets

HRH1 (Histamine H1 Receptor)ADRA1A (α1A)Acetylcholinesterase

Beyond the preview

Go deeper on Sante FX V+.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sante FX V+.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call